PETACH TIKVA, Israel, April 20, 2016 /PRNewswire/ --
Macrocure Ltd. MCUR ("Macrocure" or the "Company"), a clinical-stage biotechnology company, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report on Form 20-F, which contains Macrocure's audited financial statements, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investor.macrocure.com/annuals-proxies.cfm. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Shai Lankry, the Company's Chief Financial Officer, at +972-3-923-5556, or Shai@Macrocure.com.
About Macrocure Ltd.
Macrocure Ltd. is a clinical-stage biotechnology company that until recently was focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds. For more information, please visit http://www.Macrocure.com.
For Investors:
Shai Lankry
Macrocure Ltd.
Shai@macrocure.com
+972-3-7631409
SOURCE Macrocure Ltd.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.